UK National Health Service Productivity Lags as Doctors Strike
Analysis by the Office for National Statistics revealed that health-care productivity in the UK was 8.8% lower last year than in 2019. As the NHS accounts for 39% of total UK public spending, its problems weighed heavily on the public sector as a whole. Total public-service productivity, which includes education, defense and policing, was 4.2% lower than five years earlier, before Covid hit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Assura Plc (AGR.L) stock price, news, quote and history
Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served. A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA indices and has a secondary listing on the Johannesburg Stock Exchange. As at 31 March 2025, Assura's portfolio was valued at £3.1 billion and has a strong track record of growing financial returns and dividends for shareholders. At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S) and maintaining a Healthy Business (G).
Yahoo
23 minutes ago
- Yahoo
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
-- Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly's data on its oral obesity drug orforglipron underwhelmed investors, prompting concerns over both efficacy and tolerability. Wolfe Research described the 11.5% placebo-adjusted weight loss achieved by orforglipron at 72 weeks as 'modestly below investor expectations of 13–15%.' Analysts said the study clears a key hurdle but noted that both 'weight loss and tolerability came in light.' The highest dose of orforglipron saw treatment discontinuation rates of 24.4%, while even the lower strength showed dropout rates in the mid-teens. 'We'd flag the 10.3% and 24.4% treatment discontinuation rates... We look to results at EASD, Sept. 17th, to further gauge prescriber sentiment,' Wolfe said, maintaining an Outperform rating on LLY. Mizuho analysts echoed concerns about tolerability, calling the outcome 'clearly not the ideal outcome here despite [a] good quarter.' They pointed to a 'near 25% patient drop-out rate on the highest dose' and suggested that the unusually high 29% placebo discontinuation rate 'almost does not compute.' Despite the disappointment, Mizuho believes orforglipron still has long-term potential: '11.2% weight-loss for a pill we think is solid given ease of use... maybe more of a consumer product than a drug.' However, in the near term, the results appeared to benefit Novo Nordisk (NYSE:NVO). 'NVO rallying... as investors believe gap between the two has now narrowed to some extent,' Mizuho noted. Lilly shares are down more than 7% premarket, despite a strong quarter that included $3.38 billion in Zepbound sales and raised full-year guidance. Related articles Novo Nordisk shares jump as Eli Lilly obesity pill disappoints Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Sign in to access your portfolio
Medscape
24 minutes ago
- Medscape
Popular Diabetes Drug Ups Phimosis Risk in Men With T2D
TOPLINE: Men with type 2 diabetes (T2D) who initiated SGLT2 inhibitors showed nearly double the risk for phimosis after 1 year of treatment than those who initiated GLP-1 receptor agonists (GLP-1 RAs). This elevated risk persisted for over 8 years of follow-up. METHODOLOGY: SGLT2 inhibitors decrease hyperglycaemia by promoting glucose excretion through the kidneys, causing glucosuria, but raise concerns about an approximately threefold elevated risk for genital infections. Researchers in Denmark emulated a target trial to compare the risk for phimosis between male metformin users with T2D who initiated SGLT2 inhibitors (n = 32,543; median age, 62.8 years) and those who initiated GLP-1 RAs (n = 14,730; median age, 63.1 years) from January 2016 to December 2021. The primary outcome was a first-time inpatient or outpatient diagnosis of phimosis, with penile cancer being included as a prespecified secondary outcome. Participants were followed up for a median duration of 4 years, with a maximum follow-up duration being 8 years. TAKEAWAY: The use of SGLT2 inhibitors was associated with a nearly twofold higher risk for phimosis than the use of GLP-1 RAs at 1 year (risk ratio [RR], 1.88; 95% CI, 1.43-2.47). The elevated risk for phimosis with the use of SGLT2 inhibitors vs GLP-1 RAs persisted even after 8 years of follow-up (RR, 1.36; 95% CI, 1.14-1.61). Although the absolute risk for penile cancer was low, the results suggested that men initiating SGLT2 inhibitors had a higher 8-year cumulative risk for penile cancer than those initiating GLP-1 RAs, corresponding to an RR of 6.34 (95% CI, 1.16-34.52). IN PRACTICE: "Increased genital infections due to glucosuria in SGLT2i [SGLT2 inhibitor] users might therefore contribute to the elevated risks of both phimosis and penile cancer. Of note, any such risk must be weighed against the clear beneficial effects of SGLT2i on cardiovascular risk and overall mortality," the authors wrote. SOURCE: This study was led by Christine Ljungberg, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. It was published online on July 30, 2025, in Diabetes Care. LIMITATIONS: Detection bias may have affected the findings as SGLT2 inhibitor users are more likely to develop urogenital symptoms, potentially resulting in more frequent urologic assessments. This study identified few cases of penile cancer, limiting statistical precision for this outcome, and the median follow-up duration of 4 years may have been insufficient for thoroughly assessing the risk for penile cancer. This study lacked information on covariates such as BMI, circumcision status, ethnic diversity, socioeconomic factors, and lifestyle behaviours. DISCLOSURES: This study was supported by Aarhus University. Some authors reported giving presentations and lectures on medical research (with or without compensation), receiving research support, teaching healthcare professionals, and having other ties with various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
